-transparent.png){kind=logo}
The pharmacokinetics of nalbuphine were studied in 10 healthy volunteers on two separate occasions following administration by either the intravenous (20 mg) or oral (60 mg) route. After administration, serum concentrations of nalbuphine were measured for 12 h using a high pressure liquid chromatography assay, and pharmacokinetic parameters were derived using a three compartment model. After i.v. administration, elimination half-life was 222 (111-460) min (mean and range) and total body clearance was 1.5 (0.8-2.3) 1 min-1.Cmax after oral administration was 21.4 (6.0-36.2) ng ml-1 and tmax was 46.6 (15.3-89.0) min. Bioavailability of the oral preparation was 11.8 (6.1-20.1)%.
A R Aitkenhead, and
E S Lin, and
K J Achola
November 1987,
Journal of clinical pharmacology,
A R Aitkenhead, and
E S Lin, and
K J Achola
February 2016,
BMC pharmacology & toxicology,
A R Aitkenhead, and
E S Lin, and
K J Achola
February 1988,
The Journal of antimicrobial chemotherapy,
A R Aitkenhead, and
E S Lin, and
K J Achola
January 1986,
Biopharmaceutics & drug disposition,
A R Aitkenhead, and
E S Lin, and
K J Achola
December 1992,
Journal of pharmaceutical sciences,
A R Aitkenhead, and
E S Lin, and
K J Achola
April 1986,
European journal of clinical microbiology,
A R Aitkenhead, and
E S Lin, and
K J Achola
January 1984,
European journal of drug metabolism and pharmacokinetics,
A R Aitkenhead, and
E S Lin, and
K J Achola
August 1984,
European journal of clinical microbiology,
A R Aitkenhead, and
E S Lin, and
K J Achola
August 1989,
Clinical pharmacology and therapeutics,
A R Aitkenhead, and
E S Lin, and
K J Achola
January 1987,
European journal of clinical pharmacology,
